| pioglitazone / Generic mfg. |
NCT00212290: Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes |
|
|
| Completed | 4 | 140 | US | pioglitazone, nateglinide, placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Insulin Resistance, Type 2 Diabetes Mellitus | | 12/06 | | |
NCT00314561: The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome |
|
|
| Completed | 4 | 40 | RoW | Pioglitazone, Rosiglitazone | Korea University Anam Hospital | Metabolic Syndrome | | 12/06 | | |
NCT00926341: The Effects of Peroxisome Proliferators Activated Receptor-Gamma (PPAR-γ) Agonists on Certain Biochemical and Inflammatory Markers in Metabolic Syndrome |
|
|
| Completed | 4 | 110 | RoW | Pioglitazone, Telmisartan | Aligarh Muslim University | Metabolic Syndrome | 06/08 | 09/08 | | |
NCT00579813: Mechanisms Underlying Metabolic Syndrome in Obesity |
|
|
| Completed | 4 | 70 | US | Pioglitazone, Actos | Philip Kern, National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Metabolic Syndrome, Insulin Resistance, Prediabetes | 01/09 | 01/11 | | |
NCT00231894: Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia |
|
|
| Completed | 4 | 56 | US | Pioglitazone, Actos, Life style diet group, Placebo | Nathan Kline Institute for Psychiatric Research | Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment | 01/10 | 01/10 | | |
NCT00545233: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance. |
|
|
| Completed | 4 | 155 | US | peginterferon alfa-2a [Pegasys], Pegasys, ribavirin [Copegus], Copegus, Pioglitazone, Actos | Hoffmann-La Roche | Hepatitis C, Chronic | 12/10 | 12/10 | | |
NCT00775164: Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study |
|
|
| Withdrawn | 4 | 0 | US | pioglitazone, ACTOS, Metformin, Glucophage XR | University of Minnesota | Obesity, Insulin Resistance | 12/10 | 02/11 | | |
NCT01472497: Effects of Pioglitazone in Hypertensive Patients |
|
|
| Completed | 4 | 16 | Japan | Pioglitazone, actos | Tottori University Hospital | Hypertension, Insulin Resistance | 12/11 | 03/12 | | |
NCT00835120: Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance |
|
|
| Completed | 4 | 34 | US | Pioglitazone, Actos | University Hospitals Cleveland Medical Center, National Alliance for Research on Schizophrenia and Depression, Takeda Pharmaceuticals North America, Inc. | Metabolic Syndrome, Bipolar Depression, Insulin Resistance | 04/13 | 04/13 | | |
| Completed | 4 | 37 | US | Pioglitazone, Actos, Sugar Pill, Placebo | Stanford University, National Institutes of Health (NIH), National Institute of Mental Health (NIMH) | Major Depressive Disorder, Insulin Resistance | 01/14 | 06/14 | | |
NCT01717040: Pioglitazone for the Treatment of Bipolar Depression |
|
|
| Terminated | 4 | 37 | US | Pioglitazone, Actos, Placebo, Sugar Pill | University Hospitals Cleveland Medical Center, The Depressive and Bipolar Disorder Alternative Treatment Foundation | Bipolar Disorder, Insulin Resistance | 03/16 | 03/16 | | |
